Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Temozolomide 20 Magnetic Resonance Spectroscopy 10 Radiotherapy 9 Blood Specimen Collection 8 pembrolizumab 6 Cyclophosphamide 6 Bevacizumab 6 AZD 6244 6 Radiation 5 Specimen Handling 4 vorasidenib 3 fludarabine 3 cemiplimab 3 aflutinib 3 Surgical Procedures, Operative 3 Saline Solution 3 Radiotherapy, Intensity-Modulated 3 Radiosurgery 3 Pemetrexed 3 Granulocyte-Macrophage Colony-Stimulating Factor 3 tislelizumab 2 osimertinib 2 naxitamab 2 gallium maltolate 2 fludarabine phosphate 2 dinutuximab 2 Topotecan 2 Standard of Care 2 Spinal Puncture 2 Receptors, Interleukin-8B 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × Vortioxetine × CNS × Clear all

NCT07284628 2025-12-16

ReVoGlio

University of Zurich

Phase 2 Not yet recruiting

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡